U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938827) titled 'Evaluating the Efficacy and Safety of Inhaled SNS812 in Hospitalized Adults With Moderate to Severe COVID-19' on Nov. 10.

Brief Summary: This is an investigator-initiated, single-arm, open-label pilot study designed to explore the efficacy, safety, and tolerability of inhaled SNS812 in hospitalized adults with moderate-to-severe COVID-19.

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: COVID-19 Moderate-to-severe COVID-19

Intervention: DRUG: SNS812 (MBS-COV)

SNS812 is a potent siRNA treatment targeting mild to moderate COVID-19.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Oneness Biotech Co., Ltd.

Pu...